Safety of dupilumab in atopic patients during COVID-19 outbreak
Maddalena Napolitano, Cataldo Patruno, Angelo Ruggiero, Mariateresa Nocerino, Gabriella Fabbrocini
Abstract
"Safety of dupilumab in atopic patients during COVID-19 outbreak." Journal of Dermatological Treatment, 33(1), pp. 600–601 Disclosure statementM.N. acted as speaker for Sanofi. C.P. acted as speaker and consultant for AbbVie, Novartis, Pfizer and Sanofi. G.F. acted as speaker and consultant for AbbVie and Leo Pharma.
Topics & Concepts
DupilumabMedicineCoronavirus disease 2019 (COVID-19)Outbreak2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DermatologyFamily medicineVirologyAtopic dermatitisInternal medicineDiseaseInfectious disease (medical specialty)Dermatology and Skin DiseasesUrticaria and Related ConditionsPsoriasis: Treatment and Pathogenesis